Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1–Positive mRCC

Video

This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma.

In this video, David F. McDermott, MD, of Beth Israel Deaconess Medical Center in Boston, discusses a phase II study (IMmotion 150) that compared the anti–PD-L1 agent atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma (mRCC).

With a median follow-up of 20.7 months, results of the study showed a median progression-free survival (PFS) of 14.7 months in PD-L1–positive mRCC patients who received atezolizumab/bevacizumab vs 7.8 months in patients on sunitinib alone (hazard ratio, 0.64; 95% CI, 0.38–1.08).

McDermott highlights interesting findings from the study, including patients who achieved complete responses, and notable adverse events from the combination regimen.

The study (abstract 431) was presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.